The search for molecules to be targeted that are involved in apoptosis resistance/increased
survival and pathogenesis of onco-hematological malignancies is ongoing since these …

Although several effective treatment modalities have been developed for cancers, the
morbidity and mortality associated with cancer continues to increase every year. As one of …

The bone marrow microenvironment promotes proliferation and drug resistance in chronic
lymphocytic leukemia (CLL). Although ibrutinib is active in CLL, it is rarely able to clear …

Pediatric T-acute lymphoblastic leukemia (T-ALL) patients often display resistance to
glucocorticoid (GC) treatment. These patients, classified as prednisone poor responders …

Considering the role played by the heat shock protein of 70 kDa (HSP70) in cancer, we
characterized this protein and its major regulator, the heat shock factor 1 (HSF1), in chronic …

The treatment (ie therapy and management) of chronic lymphocytic leukemia (ie the
disease) has been improved thanks to the introduction (ie approval) of kinase inhibitors …

Simple Summary Protein kinase C (PKC) isozymes play key roles in the proliferation,
differentiation, survival, migration, invasion, apoptosis, and anticancer drug resistance of …

Introduction Bruton's tyrosine kinase (BTK) is a multifaceted player of the immune system
which has been involved in the survival of hematological malignancies but also in the …

Signalling events downstream the B‐cell receptor (BCR) are central for the survival and
progression of chronic lymphocytic leukaemia (CLL) cells. Focal adhesion kinase (FAK) …

Simple Summary The use of ibrutinib has changed the management and clinical history of
patients with multiple-treated chronic lymphocytic leukemia (CLL). Nevertheless, an …